Sale!

Supply Chain in the Pharmaceutical Industry Strategic Influences and Supply Chain Responses 1st Edition by Rob Whewell ISBN 0566086956 9780566086953

Original price was: $50.00.Current price is: $35.00.

Supply Chain in the Pharmaceutical Industry Strategic Influences and Supply Chain Responses 1st Edition Rob Whewell Digital Instant Download

Author(s): Rob Whewell
ISBN(s): 9780566086953, 0566086956
Edition: 1
File Details: PDF, 7.50 MB
Year: 2009
Language: english
SKU: EB-7008378 Category: Tag:

Supply Chain in the Pharmaceutical Industry Strategic Influences and Supply Chain Responses 1st Edition by Rob Whewell – Ebook PDF Instant Download/Delivery: 0566086956, 9780566086953
Full download Supply Chain in the Pharmaceutical Industry Strategic Influences and Supply Chain Responses 1st Edition after payment

Product details:

ISBN 10: 0566086956
ISBN 13: 9780566086953
Author: Rob Whewell

The pharmaceutical and healthcare industry is hugely complex because it involves so many markets, products, processes and intermediaries. It is also heavily regulated, global, and used by everyone at some stage in their life. No wonder the supply chain for delivery of healthcare services is often fragmented and understood only in discrete sections. Changes in one area impact upon the others, and environmental factors such as pricing, regulatory change or actions by competitors impact the whole supply chain in ways that are not easily understood or managed. Accelerating technology, the commoditization of healthcare, increasing demands from ageing populations all influence the approach that suppliers of pharmaceutical products and services worldwide need to take if they are to design and manage an effective supply chain that will be capable of: exploiting their intellectual property in a sustainable way; providing safe and continuous provision of drugs or devices; and sustaining with resilience, yet still be flexible and cost efficient. Supply Chain in the Pharmaceutical Industry offers the basis for organizations to develop their own blueprint for managing the opportunities and threats to the pharmaceutical supply chain. Using examples from companies and markets across the world Rob Whewell offers a very vivid picture of the developing trends for pharmaceutical companies; the customers and markets they serve and points to some of the elements that underpin sustainable pharmaceutical strategies. The current global banking and financial crisis illustrates the important role played by regulation. The healthcare industry is similar in scope, and complexity, yet the implications of error are worse – life threatening. This review of key industry parameters will provide senior executives in the industry and policy makers in healthcare with a broad perspective of the issues and illustrates an understanding of the task at hand.

Supply Chain in the Pharmaceutical Industry Strategic Influences and Supply Chain Responses 1st Table of contents:

Chapter 1 The Role of Technology in the Supply Chain
historical review
environmental improvements
pharmaceuticals and chemicals
diagnostic technologies
medical devices
drug delivery devices
devices that assist examination and monitoring
prosthetics
new materials
synthetic devices
how the four technological strands interact
organisational challenges

Chapter 2 Managing Supply Chain Technology
what are we trying to manage?
building a vision for the future: the ‘sine qua non’ of an effective supply chain
control
market
access
payment
organisation: local versus centralised
social priorities
what does a healthcare vision mean for pharmaceutical suppliers and medical device companies?
using a technology roadmap
measuring performance against targets
working with the roadmap
creating a favourable commercial environment
examples of investment models
developing skills and capabilities to support the vision
conclusion

Chapter 3 The Economic Significance of Healthcare Investment
a historical perspective – how the vision will be developed
international comparisons
healthcare funding reflects the values of society
the role of citizens’ expectations
healthcare investment decisions
what is the correct investment model for healthcare technology?
a note of caution
the dangers of heavy-handed control

Chapter 4 The Importance of Intellectual Property: Its Development and Protection
the parameters of investment decisions
national institute for health (usa)
the johns hopkins university (usa)
the fraunhofer institute (germany/usa)
tekes (finland)
karolinska institutet innovations ab (sweden)
buck institute (usa)
stanford research institute international (usa)
bird foundation (usa)
what makes the commercial climate conducive to long-term investment in healthcare?
drug companies’ declining window of opportunity
increasing competition and control
shareholders’ expectations
how governments can reduce confidence in investment by r&d companies
protecting the investment
the importance of protective frameworks in promoting a ‘knowledge economy’
how the pharmaceutical industry can shape its own environment
each company must balance its portfolio of intellectual property
applying good governance to decision-making
conclusion: a better business environment based on the development of intellectual property

Chapter 5 The Operational Provision of Healthcare
a model of healthcare provision
examples of the application of policy
the usa
the european union
pressures and trends into the future
conclusion

Chapter 6 Conflicting Goals within the Supply Chain
supply chain configuration
the service imperative in healthcare
the complexity of the wholesale operation
france
reimbursed products
germany
italy
integration to gain control
conclusion

Chapter 7 Diversion and Parallel Trade
introduction: three dilemmas that make for an ineffective supply chain
attitudes to risk
choice of product areas
orphan drugs
pricing and promotional policies
the impact of diversion and parallel trade on the supply chain
pricing strategies examined
profitable pricing and arbitrage – two sides of the same coin
dual pricing schemes
quota systems
allocation of product to the market channel partners
how not to promote the product
trade via the internet
conclusion

Chapter 8 Tactical Responses to Diversion
diversion is a fact of life
medical devices
diagnostics
regulatory
anti diversion regulations
special product characteristics that attract diversion
exploitation of different standards
certification approval of the manufacturing sites and processes
special formulations or product specifications
detailed quality and analytical inspections prior to release from customs
local packaging requirements
lobbying governments
supply chain management
stock allocations
bayer and adalat
syfait vs. glaxosmithkline (gsk)
direct distribution
product design, technology and branding
brand names
packaging differences
package design to prevent repackaging
a design to counter the repackers
commercial
internal management remuneration
discount structures
offers to patients
conclusion: stable the horse before it bolts

Chapter 9 Managing Compliance
background
striking the right balance
unmet need
product development and supply
product development
product supply
effective promotion, education and availability
deontology – constraint or obligation
seroxat – non-disclosure of test results?
vioxx – misrepresenting the safety of a drug?
zyprexa – stretching the boundaries?
value for money
conclusion

Chapter 10 The Case for Enhanced Patient Protection
business models for supply, distribution and dispensing to patients
manufacture of precursors
manufacture of api
production of bulk product
subcontracting issues
full-line wholesalers
alternatives to full-line wholesalers
threats to the security of the supply chain
how fraud puts patients at risk
risks to patients arising from human error
conclusion

Chapter 11 Applying Technology to Secure the Supply Chain to Patients
coding systems in common use
a solution to dispensing and administration errors: coding of drugs and patients
tagging alone does not prevent fraud
mass serialisation to identify individual products
a central database for authentication of items
network technologies to ‘close the loop’
how mass serialisation can protect patients
aegate: the potential of mass serialisation to improve patient safety
data visibility, privacy and competition law
patient privacy
commercial privacy
who benefits, and who should pay?
swot analysis for mass serialisation
strengths
weaknesses
opportunities
threats
current usage of coding
allocation of code numbers
standardisation: coding systems and their importance
standardisation of numbering systems
standardisation of technology

Chapter 12 The Importance of Information
introduction
getting value from data
demand
a basic supply chain model
supply
fixed order timing or schedule templates
fixed order quantity or kanban
managing money
revenue
procurement
transfer pricing
understand the market, control the environment

Chapter 13 The Future of Healthcare
how the system operates
possible futures
a systematic approach to understand the likely futures
possible futures for the supply and distribution of healthcare products
possible futures for supply chain control
possible futures for the industry sector

People also search for Supply Chain in the Pharmaceutical Industry Strategic Influences and Supply Chain Responses 1st:

managing supply chain uncertainty and risk in the pharmaceutical industry
    
what is pharmaceutical supply chain
    
what is supply chain management in pharmaceutical industry
    
supply chain issues in pharmaceutical industry
    
pharmaceutical supply chain companies

Tags: Rob Whewell, Supply Chain, Pharmaceutical Industry, Supply Chain